Amiloride

Generic Name: Amiloride

Brand Names: Midamor

Drug Type: Small Molecule

Chemical Formula: C_₆H_₈ClN_₇O

CAS Number: 2609-46-3

Unique Ingredient Identifier: 7DZO8EB0Z3

Background: A pyrazine compound inhibiting sodium reabsorption through sodium channels in renal epithelial cells. This inhibition creates a negative potential in the luminal membranes of principal cells, located in the distal convoluted tubule and collecting duct. Negative potential reduces secretion of potassium and hydrogen ions. Amiloride is used in conjunction with diuretics to spare potassium loss. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p705)

Indication: For use as adjunctive treatment with thiazide diuretics or other kaliuretic-diuretic agents in congestive heart failure or hypertension.

Associated Conditions: Ascites, Calcium Nephrolithiasis, Congestive Heart Failure (CHF), Hypertension, Hypokalemia, Metabolic Alkalosis, Polyuria

Clinical Trials

Beneficial Effect of Amiloride on Progression of Chronic Kidney Disease

Phase 2

Recruiting

Conditions: Chronic Kidney Disease(CKD)
Proteinuria

Interventions: Drug: amiloride
Drug: Placebo

First Posted Date: 2025-04-11

Last Posted Date: 2025-04-11

Lead Sponsor: Odense University Hospital

Target Recruit Count: 40

Registration Number: NCT06923709

Locations: 🇩🇰
Department of Nephrology, Odense University Hospital, Odense, Denmark

Natriuretic Effect of Amiloride in Relation to the Alpha Adducin Gene (ADD-AMI) RS4961 Variant

Phase 3

Completed

Conditions: Hypertension Essential
Salt Excess
Genetic Hypertension

Interventions: Drug: Amiloride

First Posted Date: 2024-05-16

Last Posted Date: 2024-05-16

Lead Sponsor: Ospedale San Raffaele

Target Recruit Count: 40

Registration Number: NCT06416735

Locations: 🇮🇹
San Raffaele Hospital, Milan, Lombardia, Italy

ARX788 for Treating Patients With HER2-low Locally Advanced Unresectable or Metastatic Breast Cancer

Phase 2

Not yet recruiting

Conditions: HER2 Low Breast Carcinoma
Triple Negative Breast Cancer
Hormone-receptor-positive Breast Cancer
Hormone Receptor Positive Breast Carcinoma

Interventions: Drug: ARX788
Procedure: Computed Tomography (CT)
Procedure: Biospecimen Collection
Drug: Amiloride

First Posted Date: 2024-01-25

Last Posted Date: 2025-03-25

Lead Sponsor: Laura Huppert, MD, BA

Target Recruit Count: 36

Registration Number: NCT06224673

Locations: 🇺🇸
University of California, San Francisco, San Francisco, California, United States

Mechanisms of Diuretic Resistance in Heart Failure, Aim 2

Phase 1

Recruiting

Conditions: Heart Failure

Interventions: Drug: Placebo
Drug: Amiloride
Drug: Bendroflumethiazide

First Posted Date: 2023-03-03

Last Posted Date: 2024-06-04

Lead Sponsor: Yale University

Target Recruit Count: 50

Registration Number: NCT05753059

Locations: 🇺🇸
Yale University, New Haven, Connecticut, United States

Treatment of Vascular Stiffness in ADPKD

Phase 4

Recruiting

Conditions: Autosomal Dominant Polycystic Kidney

Interventions: Dietary Supplement: Placebo
Dietary Supplement: Sodium chloride (NaCl)
Drug: Amiloride Hcl 5mg Tab

First Posted Date: 2022-02-08

Last Posted Date: 2023-09-07

Lead Sponsor: Erasmus Medical Center

Target Recruit Count: 54

Registration Number: NCT05228574

Locations: 🇳🇱
Erasmus University Medical Centre Rotterdam, Rotterdam, South-Holland, Netherlands

Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines (DREAM)- Amiloride vs Triamterene

Active, not recruiting

Conditions: Hypertension

Interventions: Drug: Amiloride
Drug: Triamterene

First Posted Date: 2021-11-18

Last Posted Date: 2023-07-18

Lead Sponsor: Brigham and Women's Hospital

Target Recruit Count: 146670

Registration Number: NCT05125237

Locations: 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States

Amiloride in Nephrotic Syndrome

Phase 3

Terminated

Conditions: Sodium Retention
Edema
Nephrotic Syndrome

Interventions: Drug: Furosemide
Drug: Amiloride

First Posted Date: 2021-10-15

Last Posted Date: 2025-01-14

Lead Sponsor: University Hospital Tuebingen

Target Recruit Count: 20

Registration Number: NCT05079789

Locations: 🇩🇪
University Hospital Tuebingen, Tuebingen, Baden-Wuerttemberg, Germany

AMIloride for the Treatment of Nephrogenic Diabetes Insipidus for Patients With Bipolar Disorder Treated With Lithium

Phase 4

Active, not recruiting

Conditions: Bipolar Disorder

Interventions: Drug: Anhydrous Amiloride Hydrochloride
Drug: Placebo

First Posted Date: 2021-09-16

Last Posted Date: 2025-05-09

Lead Sponsor: Assistance Publique - Hôpitaux de Paris

Target Recruit Count: 148

Registration Number: NCT05044611

Locations: 🇫🇷
Néphrologie, Hôpital Henri-Mondor, Créteil, France
🇫🇷
Physiologie Explorations fonctionnelles multidisciplinaires, Hôpital Bichat, Paris, France